Symbols / KRRO Stock $12.89 -5.26% Korro Bio, Inc.

Healthcare • Biotechnology • United States • NCM
KRRO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ram Aiyar MBA, Ph.D.
Exch · Country NCM · United States
Market Cap 185.83M
Enterprise Value 154.24M
Income -117.26M
Sales 6.39M
FCF (ttm) -49.36M
Book/sh 5.46
Cash/sh 5.21
Employees 58
Insider 10d —
IPO Oct 03, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.70
PEG —
P/S 29.07
P/B 2.36
P/C —
EV/EBITDA -1.86
EV/Sales 24.13
Quick Ratio 6.38
Current Ratio 6.90
Debt/Eq 84.54
LT Debt/Eq —
EPS (ttm) -12.48
EPS next Y -7.59
EPS Growth —
Revenue Growth -43.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-12
ROA -32.13%
ROE -110.70%
ROIC —
Gross Margin 0.00%
Oper. Margin -12.29%
Profit Margin 0.00%
Shs Outstand 14.42M
Shs Float 9.58M
Insider Own 0.57%
Instit Own 78.70%
Short Float 8.45%
Short Ratio 5.10
Short Interest 1.09M
52W High 55.89
vs 52W High -76.95%
52W Low 5.20
vs 52W Low 147.60%
Beta 2.43
Impl. Vol. 64.75%
Rel Volume 0.46
Avg Volume 219.59K
Volume 100.24K
Target (mean) $20.00
Tgt Median $22.00
Tgt Low $8.00
Tgt High $30.00
# Analysts 7
Recom None
Prev Close $13.60
Price $12.88
Change -5.26%
About

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.00
Mean price target
2. Current target
$12.89
Latest analyst target
3. DCF / Fair value
$-61.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.89
Low
$8.00
High
$30.00
Mean
$20.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 main Cantor Fitzgerald Overweight → Overweight $22
2026-03-13 up Raymond James Market Perform → Outperform $23
2026-02-19 up Clear Street Hold → Buy $18
2026-02-17 up William Blair Market Perform → Outperform —
2026-01-29 up Chardan Capital Neutral → Buy $15
2026-01-29 up HC Wainwright & Co. Neutral → Buy $20
2026-01-29 up Piper Sandler Neutral → Overweight $30
2026-01-28 up Oppenheimer Perform → Outperform $22
2026-01-28 up Cantor Fitzgerald Neutral → Overweight $21
2025-11-14 down Jones Trading Buy → Hold —
2025-11-13 down William Blair Outperform → Market Perform —
2025-11-13 down RBC Capital Outperform → Sector Perform $8
2025-11-13 down Cantor Fitzgerald Overweight → Neutral —
2025-11-13 down Chardan Capital Buy → Neutral $7
2025-11-13 down HC Wainwright & Co. Buy → Neutral —
2025-10-31 init Clear Street — → Buy $93
2025-08-13 main Chardan Capital Buy → Buy $25
2025-08-13 main Raymond James Strong Buy → Strong Buy $147
2025-08-13 main HC Wainwright & Co. Buy → Buy $90
2025-07-24 reit HC Wainwright & Co. Buy → Buy $100
News
RSS: Latest KRRO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 520 $10.60 $5,512
2026-03-10 WALKER PAUL EDWARD Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 YANG RICK Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 NEW ENTERPRISE ASSOCIATES 17 L.P. Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 BASKETT FOREST Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 MATHERS EDWARD T. Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 FLORENCE ANTHONY A JR Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 BEHBAHANI ALI Director and Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 MAKHZOUMI MOHAMAD Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
2026-03-10 CHANG CARMEN Beneficial Owner of more than 10% of a Class of Security — 207,100 $11.11 $2,300,881
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
6.39
+181.46%
2.27
0.00
0.00
Operating Revenue
6.39
+181.46%
2.27
0.00
0.00
Operating Expense
93.73
-0.47%
94.18
+11.41%
84.53
+43.28%
59.00
Research And Development
65.58
+3.05%
63.64
+11.15%
57.25
+35.66%
42.20
Selling General And Administration
28.16
-7.81%
30.55
+11.95%
27.28
+62.43%
16.80
General And Administrative Expense
28.16
-7.81%
30.55
+11.95%
27.28
+62.43%
16.80
Salaries And Wages
14.39
+9.38%
13.16
-2.11%
13.44
+49.87%
8.97
Other Gand A
13.77
-20.82%
17.39
+25.61%
13.84
+76.84%
7.83
Total Expenses
93.73
-0.47%
94.18
+11.41%
84.53
+43.28%
59.00
Operating Income
-87.34
+4.97%
-91.91
-8.73%
-84.53
-43.28%
-59.00
Total Operating Income As Reported
-121.86
-32.58%
-91.91
-8.73%
-84.53
-43.28%
-59.00
EBITDA
-83.06
+5.98%
-88.34
-9.20%
-80.90
-43.23%
-56.49
Normalized EBITDA
-48.55
+45.05%
-88.34
-9.20%
-80.90
-43.23%
-56.49
Reconciled Depreciation
4.28
+20.06%
3.56
-1.79%
3.63
+44.56%
2.51
EBIT
-87.34
+4.97%
-91.91
-8.73%
-84.53
-43.28%
-59.00
Total Unusual Items
-34.51
0.00
—
—
Total Unusual Items Excluding Goodwill
-34.51
0.00
—
—
Special Income Charges
-34.51
0.00
—
—
Impairment Of Capital Assets
30.89
0.00
—
—
Restructuring And Mergern Acquisition
3.63
0.00
—
—
Net Income
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Pretax Income
-116.62
-39.77%
-83.44
-2.83%
-81.14
-39.85%
-58.02
Net Non Operating Interest Income Expense
—
—
—
0.83
Interest Expense Non Operating
—
—
—
0.12
Net Interest Income
—
—
—
0.83
Interest Expense
—
—
—
0.12
Interest Income Non Operating
—
—
—
0.95
Interest Income
—
—
—
0.95
Other Income Expense
-29.28
-445.70%
8.47
+149.93%
3.39
+247.23%
0.98
Other Non Operating Income Expenses
5.23
-38.23%
8.47
+149.93%
3.39
+247.23%
0.98
Tax Provision
0.64
+351.77%
0.14
+422.22%
0.03
+170.00%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
-7.25
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Net Income From Continuing Operation Net Minority Interest
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Net Income From Continuing And Discontinued Operation
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Net Income Continuous Operations
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Normalized Income
-89.99
-7.67%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Net Income Common Stockholders
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Diluted EPS
—
-9.37
+82.35%
-53.08
-631.85%
-7.25
Basic EPS
—
-9.37
+82.35%
-53.08
-631.85%
-7.25
Basic Average Shares
—
8.92
+483.30%
1.53
-80.89%
8.00
Diluted Average Shares
—
8.92
+483.30%
1.53
-80.89%
8.00
Diluted NI Availto Com Stockholders
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
113.51
-49.83%
226.24
+2.06%
221.66
+200.59%
73.74
Current Assets
82.37
-37.37%
131.53
-23.85%
172.73
+202.59%
57.08
Cash Cash Equivalents And Short Term Investments
75.16
-40.40%
126.09
-24.11%
166.15
+200.73%
55.25
Cash And Cash Equivalents
21.82
-60.78%
55.64
-66.51%
166.15
+357.30%
36.33
Other Short Term Investments
53.33
-24.30%
70.45
0.00
-100.00%
18.91
Receivables
0.97
-42.87%
1.70
0.00
—
Accounts Receivable
0.97
-42.87%
1.70
0.00
—
Restricted Cash
—
0.00
-100.00%
3.56
+490.88%
0.60
Other Current Assets
6.25
+66.99%
3.74
+24.08%
3.02
+144.72%
1.23
Total Non Current Assets
31.13
-67.13%
94.71
+93.54%
48.94
+193.75%
16.66
Net PPE
16.22
-68.53%
51.55
+20.39%
42.81
+260.09%
11.89
Gross PPE
26.79
-54.49%
58.87
+16.22%
50.66
+213.76%
16.14
Accumulated Depreciation
-10.57
-44.23%
-7.33
+6.55%
-7.84
-84.30%
-4.25
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.74
-36.32%
1.16
+60.94%
0.72
+4.64%
0.69
Construction In Progress
0.00
-100.00%
0.11
-98.70%
8.24
+302.24%
2.05
Other Properties
16.37
-53.45%
35.17
-8.27%
38.34
+266.34%
10.46
Leases
9.68
-56.85%
22.44
+568.59%
3.36
+14.11%
2.94
Investments And Advances
10.03
-72.86%
36.96
0.00
—
Other Non Current Assets
4.88
-21.31%
6.20
+1.36%
6.12
+28.33%
4.77
Total Liabilities Net Minority Interest
62.07
-5.71%
65.83
+27.19%
51.75
-70.05%
172.77
Current Liabilities
11.94
-20.21%
14.96
-23.22%
19.48
+123.92%
8.70
Payables And Accrued Expenses
5.15
-15.68%
6.11
-30.19%
8.75
+196.85%
2.95
Payables
1.65
-58.64%
3.99
-45.16%
7.28
+179.46%
2.60
Accounts Payable
1.65
-58.64%
3.99
-45.16%
7.28
+179.46%
2.60
Current Accrued Expenses
3.50
+65.27%
2.12
+43.76%
1.47
+328.49%
0.34
Pensionand Other Post Retirement Benefit Plans Current
4.04
+7.07%
3.77
-52.19%
7.90
+200.91%
2.62
Current Debt And Capital Lease Obligation
2.67
+108.10%
1.28
-35.51%
1.99
-31.84%
2.92
Current Capital Lease Obligation
2.67
+108.10%
1.28
-35.51%
1.99
-31.84%
2.92
Current Deferred Liabilities
0.00
-100.00%
3.51
0.00
0.00
Current Deferred Revenue
0.00
-100.00%
3.51
0.00
—
Other Current Liabilities
0.07
-74.73%
0.28
-67.10%
0.84
+306.76%
0.21
Total Non Current Liabilities Net Minority Interest
50.13
-1.45%
50.87
+57.63%
32.27
-80.33%
164.07
Long Term Debt And Capital Lease Obligation
40.81
-6.13%
43.48
+39.29%
31.22
+14835.89%
0.21
Long Term Capital Lease Obligation
40.81
-6.13%
43.48
+39.29%
31.22
+14835.89%
0.21
Non Current Deferred Liabilities
7.83
+32.53%
5.91
0.00
0.00
Non Current Deferred Revenue
7.83
+32.53%
5.91
0.00
—
Other Non Current Liabilities
1.48
+0.61%
1.47
+39.79%
1.05
—
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
163.86
Stockholders Equity
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Common Stock Equity
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Capital Stock
0.01
+0.00%
0.01
+12.50%
0.01
0.00
Common Stock
0.01
+0.00%
0.01
+12.50%
0.01
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
9.42
+0.43%
9.38
+16.97%
8.02
+0.19%
8.00
Ordinary Shares Number
9.42
+0.43%
9.38
+16.97%
8.02
+0.19%
8.00
Additional Paid In Capital
435.06
+1.95%
426.72
+20.92%
352.91
+12472.43%
2.81
Retained Earnings
-383.85
-43.99%
-266.59
-45.67%
-183.00
-79.71%
-101.83
Gains Losses Not Affecting Retained Earnings
0.21
-20.90%
0.27
0.00
+100.00%
-0.01
Other Equity Adjustments
0.21
-20.90%
0.27
—
-0.01
Total Equity Gross Minority Interest
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Total Capitalization
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Working Capital
70.44
-39.58%
116.57
-23.93%
153.25
+216.74%
48.38
Invested Capital
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Total Debt
43.49
-2.86%
44.77
+34.81%
33.21
+960.93%
3.13
Capital Lease Obligations
43.49
-2.86%
44.77
+34.81%
33.21
+960.93%
3.13
Net Tangible Assets
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Tangible Book Value
51.44
-67.93%
160.41
-5.59%
169.91
+271.57%
-99.03
Investmentin Financial Assets
10.03
-72.86%
36.96
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-78.56
-30.77%
-60.07
+10.71%
-67.28
-25.42%
-53.65
Cash Flow From Continuing Operating Activities
-78.56
-30.77%
-60.07
+10.71%
-67.28
-25.42%
-53.65
Net Income From Continuing Operations
-117.26
-40.30%
-83.58
-2.97%
-81.17
-39.87%
-58.03
Depreciation Amortization Depletion
4.28
+20.06%
3.56
-1.79%
3.63
+44.56%
2.51
Depreciation
4.28
+20.06%
3.56
-1.79%
3.63
+44.56%
2.51
Depreciation And Amortization
4.28
+20.06%
3.56
-1.79%
3.63
+44.56%
2.51
Other Non Cash Items
0.73
-77.97%
3.31
-8.20%
3.61
+138.44%
1.51
Stock Based Compensation
7.66
+71.56%
4.46
+87.40%
2.38
+108.86%
1.14
Asset Impairment Charge
30.89
0.00
—
—
Operating Gains Losses
0.06
-82.35%
0.36
+449.23%
0.07
—
Gain Loss On Sale Of PPE
0.06
-82.35%
0.36
+449.23%
0.07
0.00
Change In Working Capital
-4.43
-132.57%
13.59
+217.32%
4.28
+776.62%
-0.63
Change In Receivables
0.73
+142.87%
-1.70
0.00
—
Changes In Account Receivables
0.73
+142.87%
-1.70
0.00
—
Change In Prepaid Assets
-1.67
-130.58%
-0.73
-229.87%
0.56
+2096.43%
-0.03
Change In Payables And Accrued Expense
-0.88
+83.43%
-5.31
-221.51%
4.37
+154.66%
1.72
Change In Accrued Expense
1.43
+136.05%
-3.97
-412.52%
1.27
+3356.41%
-0.04
Change In Payable
-2.31
-72.33%
-1.34
-143.26%
3.10
+76.64%
1.75
Change In Account Payable
-2.31
-72.33%
-1.34
-143.26%
3.10
+76.64%
1.75
Change In Other Working Capital
-1.59
-116.87%
9.43
—
—
Change In Other Current Assets
0.27
-20.59%
0.34
+117.11%
-1.99
-1515.45%
-0.12
Change In Other Current Liabilities
-1.28
-111.07%
11.56
+761.89%
1.34
+161.01%
-2.20
Investing Cash Flow
43.99
+135.67%
-123.35
-1204.86%
11.16
+0.94%
11.06
Cash Flow From Continuing Investing Activities
43.99
+135.67%
-123.35
-1204.86%
11.16
+0.94%
11.06
Net PPE Purchase And Sale
-0.52
+97.11%
-17.90
-128.46%
-7.84
-50.35%
-5.21
Purchase Of PPE
-0.52
+97.11%
-17.90
-128.46%
-7.84
-50.35%
-5.21
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.52
+97.11%
-17.90
-128.46%
-7.84
-50.35%
-5.21
Net Investment Purchase And Sale
44.51
+142.21%
-105.44
-654.97%
19.00
+16.76%
16.27
Purchase Of Investment
-26.19
+82.10%
-146.34
0.00
+100.00%
-37.21
Sale Of Investment
70.70
+72.86%
40.90
+115.26%
19.00
-64.48%
53.48
Financing Cash Flow
0.69
-99.01%
69.36
-63.06%
187.76
+1043016.67%
0.02
Cash Flow From Continuing Financing Activities
0.69
-99.01%
69.36
-63.06%
187.76
+1043016.67%
0.02
Net Common Stock Issuance
0.00
-100.00%
67.39
-42.53%
117.25
0.00
Proceeds From Stock Option Exercised
0.69
-65.23%
1.97
+180.63%
0.70
+1032.26%
0.06
Net Other Financing Charges
—
—
24.35
+55443.18%
-0.04
Changes In Cash
-33.88
+70.30%
-114.07
-186.65%
131.64
+409.26%
-42.57
Effect Of Exchange Rate Changes
0.06
+1700.00%
-0.00
0.00
—
Beginning Cash Position
59.05
-65.89%
173.12
+317.39%
41.48
-50.65%
84.04
End Cash Position
25.23
-57.27%
59.05
-65.89%
173.12
+317.39%
41.48
Free Cash Flow
-79.08
-1.41%
-77.98
-3.80%
-75.12
-27.63%
-58.86
Income Tax Paid Supplemental Data
0.00
-99.29%
0.14
+422.22%
0.03
+145.45%
0.01
Amortization Of Securities
-0.49
+72.56%
-1.78
-2127.50%
-0.08
+44.83%
-0.14
Common Stock Issuance
0.00
-100.00%
67.39
-42.53%
117.25
0.00
Issuance Of Capital Stock
0.00
-100.00%
67.39
-58.59%
162.71
0.00
Net Preferred Stock Issuance
—
0.00
-100.00%
45.46
0.00
Preferred Stock Issuance
—
0.00
-100.00%
45.46
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category